{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:47:59Z","timestamp":1774471679947,"version":"3.50.1"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"DOI":"10.3389\/fpubh.2020.00361","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T06:08:06Z","timestamp":1595916486000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Do Vaccines Have a Role as a Cause of Autoimmune Neurological Syndromes?"],"prefix":"10.3389","volume":"8","author":[{"given":"Nicola","family":"Principi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1016\/j.vaccine.2016.10.025","article-title":"Vaccine impact: benefits for human health","volume":"34","author":"Doherty","year":"2016","journal-title":"Vaccine."},{"key":"B2","first-page":"1","article-title":"A short history of vaccination","volume-title":"Vaccines","author":"Plotkin","year":"2012"},{"key":"B3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fpubh.2015.00269","article-title":"Vaccines through centuries: major cornerstones of global health","volume":"3","author":"Hajj Hussein","year":"2015","journal-title":"Front Public Health."},{"key":"B4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1586\/14760584.2015.964212","article-title":"Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications","volume":"14","author":"Dub\u00e9","year":"2015","journal-title":"Expert Rev Vaccines."},{"key":"B5","unstructured":"Emergencies Preparedness, Response. Measles-Global Situation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40272-020-00385-4","article-title":"Vaccine hesitancy: a growing concern","volume":"22","author":"Kennedy","year":"2020","journal-title":"Paediatr Drugs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1517\/14740338.2016.1167869","article-title":"Adverse events following immunization: real causality and myths","volume":"15","author":"Principi","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/WCO.0000000000000318","article-title":"Vaccine-associated inflammatory diseases of the central nervous system: from signals to causation","volume":"29","author":"Nguyen","year":"2016","journal-title":"Curr Opin Neurol."},{"key":"B9","article-title":"Institute of Medicine","volume-title":"Adverse Effects of Vaccines: Evidence and Causality","author":"Stratton","year":"2011"},{"key":"B10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.mcna.2018.10.004","article-title":"Multiple sclerosis and autoimmune neurology of the central nervous system","volume":"103","author":"Galetta","year":"2019","journal-title":"Med Clin North Am."},{"key":"B11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00281-009-0178-z","article-title":"The pathological spectrum of CNS inflammatory demyelinating diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Semin Immunopathol."},{"key":"B12","volume-title":"The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects: Workshop Summary","author":"Knobler","year":"2004"},{"key":"B13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/00019052-200206000-00019","article-title":"Immunopathogenesis of acute transverse myelitis","volume":"15","author":"Kerr","year":"2002","journal-title":"Curr Opin Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WCO.0000000000000205","article-title":"Advances in the immunopathogenesis of multiple sclerosis","volume":"28","author":"Yadav","year":"2015","journal-title":"Curr Opin Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"E50","DOI":"10.3390\/vaccines8010050","article-title":"Infections, vaccines and autoimmunity: a multiple sclerosis perspective","volume":"8","author":"Jakimovski","year":"2020","journal-title":"Vaccines (Basel)."},{"key":"B16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.281.5377.630","article-title":"A shadow falls on hepatitis B vaccination effort","volume":"281","author":"Marshall","year":"1998","journal-title":"Science."},{"key":"B17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJM200102013440502","article-title":"Hepatitis B vaccination and the risk of multiple sclerosis","volume":"344","author":"Ascherio","year":"2001","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1586\/14760584.1.4.461","article-title":"Hepatitis B vaccine and risk of multiple sclerosis","volume":"1","author":"DeStefano","year":"2002","journal-title":"Expert Rev Vaccines."},{"key":"B19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(99)02991-8","article-title":"School-based hepatitis B vaccination programme and adolescent multiple sclerosis","volume":"355","author":"Sadovnick","year":"2000","journal-title":"Lancet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1212\/01.wnl.0000335762.42177.07","article-title":"Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood","volume":"72","author":"Mikaeloff","year":"2009","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.vaccine.2019.02.046","article-title":"Hepatitis B vaccination and central demyelination - history, description and observed\/expected analyses of 624 cases reported to the French pharmacovigilance over a 20-year period","volume":"37","author":"Mouchet","year":"2019","journal-title":"Vaccine."},{"key":"B22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12026-014-8574-4","article-title":"Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination","volume":"60","author":"Le","year":"2014","journal-title":"Immunol Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1080\/21645515.2017.1423155","article-title":"Association between Human Papilloma Virus (HPV) vaccination and risk of multiple sclerosis: a systematic review","volume":"14","author":"Meggiolaro","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.phrs.2018.04.007","article-title":"Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis","volume":"132","author":"Mouchet","year":"2018","journal-title":"Pharmacol Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/INF.0000000000002569","article-title":"Systematic review and meta-analysis of postlicensure observational studies on human papillomavirus vaccination and autoimmune and other rare adverse events","volume":"39","author":"Willame","year":"2020","journal-title":"Pediatr Infect Dis J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"d5956","DOI":"10.1136\/bmj.d5956","article-title":"Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden","volume":"343","author":"Bardage","year":"2011","journal-title":"BMJ."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1001\/jama.251.20.2672","article-title":"Swine flu vaccine and multiple sclerosis","volume":"251","author":"Kurland","year":"1984","journal-title":"JAMA."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/cid\/ciw607","article-title":"Acute demyelinating events following vaccines: a case-centered analysis","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00415-016-8263-4","article-title":"Vaccines and multiple sclerosis: a systematic review","volume":"264","author":"Mailand","year":"2017","journal-title":"J Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1016\/j.vaccine.2018.05.063","article-title":"Vaccines and the risk of acute disseminated encephalomyelitis","volume":"36","author":"Chen","year":"2018","journal-title":"Vaccine."},{"key":"B32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3329\/jhpn.v28i6.6602","article-title":"Quantifying the association between campylobacter infection and guillain-Barr\u00e9 syndrome: a systematic review","volume":"28","author":"Poropatich","year":"2010","journal-title":"J Health Popul Nutr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1212\/WNL.56.6.758","article-title":"Preceding infections, immune factors, and outcome in Guillain-Barr\u00e9 syndrome","volume":"56","author":"Hadden","year":"2001","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","article-title":"The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study","volume":"51","author":"Jacobs","year":"1998","journal-title":"Neurology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barr\u00e9 syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/00207454.2015.1033621","article-title":"Guillain-Barr\u00e9 syndrome following chickenpox: a case series","volume":"126","author":"Tatarelli","year":"2016","journal-title":"Int J Neurosci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s10072-014-1841-2","article-title":"Guillain-Barr\u00e9 syndrome following measles infection: case report and review of the literature","volume":"35","author":"Filia","year":"2014","journal-title":"Neurol Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/brain\/123.10.2171","article-title":"Haemophilus influenzae infection and Guillain-Barr\u00e9 syndrome","volume":"123","author":"Mori","year":"2000","journal-title":"Brain."},{"key":"B41","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","article-title":"GBS Classification Group. Guillain-Barr\u00e9 and miller fisher syndromes\u2013new diagnostic classification","volume":"10","author":"Wakerley","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1085-9489.2005.0010207.x","article-title":"Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"10","author":"Allen","year":"2005","journal-title":"J Peripher Nerv Syst."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1074\/mcp.M115.056036","article-title":"The pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): proteo-peptidomic and immunological profiling of physiological fluids","volume":"15","author":"Ziganshin","year":"2016","journal-title":"Mol Cell Proteomics."},{"key":"B44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0165-5728(96)00059-8","article-title":"Association of anti-GM2 antibodies in Guillain-Barr\u00e9 syndrome with acute cytomegalovirus infection","volume":"68","author":"Irie","year":"1996","journal-title":"J Neuroimmunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.880180407","article-title":"Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection","volume":"18","author":"Kusunoki","year":"1995","journal-title":"Muscle Nerve."},{"key":"B46","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ana.1012","article-title":"Animal model of axonal Guillain-Barr\u00e9 syndrome induced by sensitization with GM1 ganglioside","volume":"49","author":"Yuki","year":"2001","journal-title":"Ann Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jns.2008.05.006","article-title":"Validation of a rabbit model of neuropathy induced by immunization with gangliosides","volume":"272","author":"Moyano","year":"2008","journal-title":"J Neurol Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jneuroim.2005.12.005","article-title":"Experimental axonopathy induced by immunization with Campylobacter jejuni lipopolysaccharide from a patient with Guillain-Barr\u00e9 syndrome","volume":"174","author":"Caporale","year":"2006","journal-title":"J Neuroimmunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1016\/j.vaccine.2018.05.119","article-title":"Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome","volume":"37","author":"Principi","year":"2019","journal-title":"Vaccine."},{"key":"B50","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/cid\/ciz135","article-title":"Principal controversies in vaccine safety in the United States","volume":"69","author":"DeStefano","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B51","unstructured":"Merck Sharp & Dohme Limited. MMRVAXPRO"},{"key":"B52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(94)90917-2","article-title":"Guillain-Barr\u00e9 syndrome after measles, mumps, and rubella vaccine","volume":"343","author":"Morris","year":"1994","journal-title":"Lancet."},{"key":"B53","first-page":"1636","article-title":"An slutningen till vaccination mot morbilli, parotit och rubella","volume":"81","author":"Jonse","year":"1984","journal-title":"L\u00e4kartidningen."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1136\/bmj.295.6608.1264","article-title":"Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella","volume":"295","author":"B\u00f6ttiger","year":"1987","journal-title":"BMJ."},{"key":"B55","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/0264-410X(90)90245-H","article-title":"Measles mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. tolerability and analysis of spontaneously reported side effects","volume":"8","author":"Fescharek","year":"1990","journal-title":"Vaccine."},{"key":"B56","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0140-6736(95)90302-X","article-title":"Gait disturbances after measles, mumps, and rubella vaccine","volume":"345","author":"Plesner","year":"1995","journal-title":"Lancet."},{"key":"B57","volume-title":"Adverse Events Associated With Childhood Vaccines: Evidence Bearing on Causality. Measles and Mumps Vaccines","year":"2011"},{"key":"B58","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1067\/mpd.2001.111165","article-title":"Risk of Guillain-Barr\u00e9 syndrome after measles-mumps-rubella vaccination","volume":"138","author":"Patja","year":"2001","journal-title":"J Pediatr."},{"key":"B59","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1016\/j.vaccine.2008.07.014","article-title":"Relationship between occurrence of Guillain-Barre syndrome and mass campaign of measles and rubella immunization in Iranian 5\u201314 years old children","volume":"26","author":"Esteghamati","year":"2008","journal-title":"Vaccine."},{"key":"B60","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0140-6736(96)07408-9","article-title":"Measles vaccination and Guillain-Barr\u00e9 syndrome","volume":"349","author":"da Silveira","year":"1997","journal-title":"Lancet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2million young girls in France","volume":"35","author":"Miranda","year":"2017","journal-title":"Vaccine."},{"key":"B62","unstructured":"Safety of HPV Vaccines"},{"key":"B63","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J Autoimmun."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papilloma virus vaccine: a self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine."},{"key":"B65","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/pds.3554","article-title":"Pooled analysis of large and long-term safety data from the human papillomavirus-16\/18-AS04-adjuvanted vaccine clinical trial programme","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B66","doi-asserted-by":"publisher","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine."},{"key":"B67","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep."},{"key":"B68","first-page":"393","article-title":"Meeting of the global advisory committee on vaccine safety, 7\u20138 June 2017","volume":"92","year":"2017","journal-title":"Weekly Epidemiol Record."},{"key":"B69","first-page":"1023","article-title":"Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine\u2013United States, June-July 2005","volume":"54","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B70","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.vaccine.2009.10.050","article-title":"MCV vaccination in the presence of vaccine associated Guillain-Barr\u00e9 Syndrome risk: a decision analysis approach","volume":"28","author":"Cho","year":"2010","journal-title":"Vaccine."},{"key":"B71","first-page":"364","article-title":"Update: Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine\u2014United States, October 2005\u2013 February 2006","volume":"55","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1016\/j.vaccine.2017.09.032","article-title":"Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine","volume":"35","author":"Hansen","year":"2017","journal-title":"Vaccine."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/pds.3321","article-title":"Risk of Guillain-Barr\u00e9 syndrome after meningococcal conjugate vaccination","volume":"21","author":"Velentgas","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/pds.3353","article-title":"No risk of Guillain-Barr\u00e9 syndrome found after meningococcal conjugate vaccination in two large cohort studies","volume":"21","author":"Yih","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B75","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep."},{"key":"B76","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/oxfordjournals.aje.a113809","article-title":"An epidemiologic and clinical-evaluation of Guillain-Barre-syndrome reported in association with the administration of swine influenza vaccines","volume":"119","author":"Langmuir","year":"1984","journal-title":"Am J Epidemiol."},{"key":"B77","volume-title":"Immunization Safety Review: Influenza Vaccines and Neurological Complications","year":"2003"},{"key":"B78","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barre syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.amepre.2010.05.022","article-title":"Evaluation of Guillain-Barre syndrome among recipients of influenza vaccine in 2000 and 2001","volume":"39","author":"Burwen","year":"2010","journal-title":"Am J Prev Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/aje\/kwp345","article-title":"Near realtime surveillance for influenza vaccine safety: proof-of-concept in the vaccine safety datalink project","volume":"171","author":"Greene","year":"2010","journal-title":"Am J Epidemiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(06)68176-2","article-title":"Guillain-Barre syndrome\u2014reply","volume":"367","author":"Hughes","year":"2006","journal-title":"Lancet."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/archinte.166.20.2217","article-title":"Guillain-Barre syndrome after influenza vaccination in adults\u2014a population-based study","volume":"166","author":"Juurlink","year":"2006","journal-title":"Arch Int Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.248.6.698","article-title":"Guillain-Barr\u00e8 syndrome in the United States, 1979\u20131980 and 1980\u20131981\u2014lack of an association with influenza vaccination","volume":"248","author":"Kaplan","year":"1982","journal-title":"JAMA."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","article-title":"The Guillain-Barre syndrome and the 1993 and 1993\u20131994 influenza vaccines","volume":"339","author":"Lasky","year":"1998","journal-title":"N Engl J Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","article-title":"Association between Guillain-Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis","volume":"381","author":"Salmon","year":"2013","journal-title":"Lancet."},{"key":"B86","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2012.7342","article-title":"Risk of Guillain-Barr\u00e9 syndrome following H1N1 influenza vaccination in Quebec","volume":"308","author":"De Wals","year":"2012","journal-title":"JAMA."},{"key":"B87","doi-asserted-by":"publisher","first-page":"d3908","DOI":"10.1136\/bmj.d3908","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe","volume":"343","author":"Dieleman","year":"2011","journal-title":"BMJ."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1016\/j.vaccine.2017.03.087","article-title":"Near realtime surveillance for Guillain-Barr\u00e9 syndromeafter influenza vaccination among the medicare population, 2010\/11 to 2013\/14","volume":"35","author":"Sandhu","year":"2017","journal-title":"Vaccine."},{"key":"B89","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the national influenza immunization program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2105\/AJPH.2013.301651","article-title":"Cumulative risk of Guillain-Barr\u00e9 syndrome among vaccinated and unvaccinated populations during the 2009. H1N1 influenza pandemic","volume":"104","author":"Vellozzi","year":"2014","journal-title":"Am J Public Health."},{"key":"B91","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barr\u00e9 Syndrome following Influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine."},{"key":"B92","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1473-3099(13)70104-X","article-title":"Risk of Guillain-Barr\u00e9 syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study","volume":"13","author":"Kwong","year":"2013","journal-title":"Lancet Infect Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0264-410X(02)00163-9","article-title":"Workshop summary Aluminum in vaccines","volume":"20","author":"Eickhoff","year":"2002","journal-title":"Vaccine."},{"key":"B94","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1016\/j.vaccine.2018.08.036","article-title":"Aluminum in vaccines: does it create a safety problem?","volume":"36","author":"Principi","year":"2018","journal-title":"Vaccine."},{"key":"B95","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00420-007-0191-2","article-title":"Longitudinal study on potential neurotoxic effects of aluminum: I. assessment of exposure and neurobehavioral performance of Al welders in the train and truck construction industry over 4 years","volume":"81","author":"Kiesswetter","year":"2007","journal-title":"Int Arch Occup Environ Health."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00420-009-0414-9","article-title":"Longitudinal study on potential neurotoxic effects of aluminum: II. assessment of exposure and neurobehavioral performance of Al welders in the automobile industry over 4 years","volume":"82","author":"Kiesswetter","year":"2009","journal-title":"Int Arch Occup Environ Health."},{"key":"B97","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1017\/S0029665111000498","article-title":"Aluminum exposure from parenteral nutrition in preterm infants and later health outcomes during childhood and adolescence","volume":"70","author":"Fewtrell","year":"2011","journal-title":"Proc Nutr Soc."},{"key":"B98","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/JOM.0000000000000487","article-title":"Occupational exposure to aluminum and Alzheimer disease: a meta-analysis","volume":"57","author":"Virk","year":"2015","journal-title":"J Occup Environ Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1192\/bjp.168.2.244","article-title":"A case-control study of Alzheimer's disease and aluminum occupation","volume":"168","author":"Salib","year":"1996","journal-title":"Br J Psychiatry."},{"key":"B100","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jinorgbio.2013.07.022","article-title":"Tomljenovic L Administration of aluminum to neonatal mice in vaccine-relevant amounts is associated with adverse long-term neurological outcomes","volume":"128","author":"Shaw","year":"2013","journal-title":"J Inorg Biochem."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.jinorgbio.2011.08.008","article-title":"Do aluminum vaccine adjuvants contribute to the rising prevalence of autism?","volume":"105","author":"Tomljenovic","year":"2011","journal-title":"J Inorg Biochem."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.2174\/092986711795933740","article-title":"Aluminum vaccine adjuvants: are they safe?","volume":"18","author":"Tomljenovic","year":"2011","journal-title":"Cur Med Chem."},{"key":"B103","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.acap.2017.09.003","article-title":"Blood and hair aluminum levels, vaccine history, and early infant development: a cross-sectional study","volume":"18","author":"Karwowski","year":"2018","journal-title":"Acad Pediatr."},{"key":"B104","first-page":"44","volume-title":"Aluminum Miller's review of critical vaccine studies. 400 important scientific papers summarized for parents and researchers","author":"Miller","year":"2016"},{"key":"B105","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jaut.2010.07.003","article-title":"\u2018ASIA\u2019\u2014autoimmune\/inflammatory syndrome induced by adjuvants","volume":"36","author":"Shoenfeld","year":"2011","journal-title":"J Autoimmun."},{"key":"B106","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1177\/0961203316686406","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome)\u2014an update","volume":"26","author":"Watad","year":"2017","journal-title":"Lupus."},{"key":"B107","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2014.03.003","article-title":"Sjogren's syndrome: another facet of the autoimmune\/inflammatory syndrome induced by adjuvants (ASIA)","volume":"51","author":"Colafrancesco","year":"2014","journal-title":"J Autoimmun."},{"key":"B108","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.phrs.2014.10.005","article-title":"Is narcolepsy a classical autoimmune disease?","volume":"92","author":"Arango","year":"2015","journal-title":"Pharmacol Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12026-014-8622-0","article-title":"Adjuvants and lymphoma risk as part of the ASIA spectrum","volume":"61","author":"Butnaru","year":"2015","journal-title":"Immunol Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10067-017-3748-9","article-title":"The autoimmune\/inflammatory syndrome induced by adjuvants (ASIA)\/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry","volume":"37","author":"Watad","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12026-014-8586-","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (ASIA): clues and pitfalls in the pediatric background","volume":"60","author":"Esposito","year":"2014","journal-title":"Immunol Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.jaip.2017.06.033","article-title":"Evidence refuting the existence of autoimmune\/autoinflammatory syndrome induced by adjuvants (ASIA)","volume":"5","author":"Ameratunga","year":"2017","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0140-6736(03)14802-7","article-title":"Vaccination and autoimmune disease: what is the evidence?","volume":"362","author":"Wraith","year":"2003","journal-title":"Lancet."},{"key":"B114","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1177\/0961203307078225","article-title":"Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus","volume":"16","author":"Kuruma","year":"2007","journal-title":"Lupus."},{"key":"B115","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jaci.2011.09.007","article-title":"Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality","volume":"129","author":"Ameratunga","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1002\/art.10465","article-title":"HLADRB1*01 and macrophagic myofasciitis","volume":"46","author":"Guis","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B117","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J Interferon Cytokine Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/0300974051007913","article-title":"Macrophagic myofasciitis unrelated to vaccination","volume":"34","author":"Park","year":"2005","journal-title":"Scand J Rheumatol."},{"key":"B119","unstructured":"Thimerosal and Vaccines."},{"key":"B120","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/jat.2855","article-title":"Toxicity of ethylmercury (and Thimerosal): a comparison with methylmercury","volume":"33","author":"D\u00f3rea","year":"2013","journal-title":"J Appl Toxicol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"129299","DOI":"10.1016\/j.bbagen.2019.02.001","article-title":"Mercury-induced inflammation and autoimmunity","volume":"1863","author":"Pollard","year":"2019","journal-title":"Biochim Biophys Acta Gen Subj."},{"key":"B122","doi-asserted-by":"publisher","first-page":"108352","DOI":"10.1016\/j.clim.2020.108352","article-title":"Mercury-induced autoimmunity: drifting from micro to macro concerns on autoimmune disorders","volume":"213","author":"Bj\u00f8rklund","year":"2020","journal-title":"Clin Immunol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1006\/jaut.1997.9997","article-title":"Major histocompatibility complex class II antigens are required for both cytokine production proliferation induced by mercuric chloride in vitro","volume":"10","author":"Hu","year":"1997","journal-title":"J Autoimmun"},{"key":"B124","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1006\/clin.1997.4405","article-title":"Class II haplotype differentially regulates immune response in HgCl2- treated mice","volume":"84","author":"Hanley","year":"1997","journal-title":"Clin Immunol Immunopathol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1542\/peds.2003-1176-L","article-title":"Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association","volume":"114","author":"Heron","year":"2004","journal-title":"Pediatrics."},{"key":"B126","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1542\/peds.2010-0309","article-title":"Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism","volume":"126","author":"Price","year":"2010","journal-title":"Pediatrics."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1056\/NEJMoa071434","article-title":"Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years","volume":"357","author":"Thompson","year":"2007","journal-title":"N Engl J Med."},{"key":"B128","unstructured":"Global vaccine safety. Thiomersal and vaccines: questions and answers"},{"key":"B129","unstructured":"Thimerosal in vaccines"},{"key":"B130","unstructured":"EMEA public statement on thiomersal in vaccines for human use. Recent evidences support safety of thiomersal-containing vaccines"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpubh.2020.00361\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T06:08:15Z","timestamp":1595916495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpubh.2020.00361\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":130,"alternative-id":["10.3389\/fpubh.2020.00361"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2020.00361","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"article-number":"361"}}